4.4 Article

Disenrollment from medicare managed care among beneficiaries with and without a cancer diagnosis

Journal

JOURNAL OF THE NATIONAL CANCER INSTITUTE
Volume 100, Issue 14, Pages 1013-1021

Publisher

OXFORD UNIV PRESS INC
DOI: 10.1093/jnci/djn208

Keywords

-

Categories

Funding

  1. AHRQ HHS [R03 HS14831] Funding Source: Medline
  2. NCI NIH HHS [R21 CA98353] Funding Source: Medline

Ask authors/readers for more resources

Background Medicare managed care may offer enrollees lower out-of-pocket costs and provide benefits that are not available in the traditional fee-for-service Medicare program. However, managed care plans may also restrict provider choice in an effort to control costs. We compared rates of voluntary disenrollment from Medicare managed care to traditional fee-for-service Medicare among Medicare managed care enrollees with and without a cancer diagnosis. Methods We identified Medicare managed care enrollees aged 65 years or older who were diagnosed with a first primary breast (n = 28 331), colorectal (n = 26 494), prostate (n = 29 046), or lung (n = 31 243) cancer from January 1, 1995, through December 31, 2002, in Surveillance, Epidemiology, and End Results (SEER) cancer registry records linked with Medicare enrollment files. Cancer patients were pair-matched to cancer-free enrollees by age, sex, race, and geographic location. We estimated rates of voluntary disenrollment to fee-for-service Medicare in the 2 years after each cancer patient's diagnosis, adjusted for plan characteristics and Medicare managed care penetration, by use of Cox proportional hazards regression. Results In the 2 years after diagnosis, cancer patients were less likely to disenroll from Medicare managed care than their matched cancer-free peers (for breast cancer, adjusted hazard ratio [HR] for disenrollment = 0.78, 95% confidence interval [CI] = 0.74 to 0.82; for colorectal cancer, HR = 0.84, 95% CI = 0.80 to 0.88; for prostate cancer, HR = 0.86, 95% CI = 0.82 to 0.90; and for lung cancer, HR = 0.81, 95% CI = 0.76 to 0.86). Results were consistent across strata of age, sex, race, SEER registry, and cancer stage. Conclusion A new cancer diagnosis between 1995 and 2002 did not precipitate voluntary disenrollment from Medicare managed care to traditional fee-for-service Medicare.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Gastroenterology & Hepatology

A perioperative multidisciplinary care bundle reduces surgical site infections in patients undergoing synchronous colorectal and liver resection

Lauren S. Tufts, Emma D. Jarnagin, Jessica R. Flynn, Mithat Gonen, Jose G. Guillem, Philip B. Paty, Garrett M. Nash, Joshua J. Smith, Iris H. Wei, Emmanouil Pappou, Michael I. D'Angelica, Peter J. Allen, T. Peter Kingham, Vinod P. Balachandran, Jeffrey A. Drebin, Julio Garcia-Aguilar, William R. Jarnagin, Martin R. Weiser

Article Gastroenterology & Hepatology

Preoperative risk prediction for intraductal papillary mucinous neoplasms by quantitative CT image analysis

Marc A. Attiyeh, Jayasree Chakraborty, Lior Gazit, Liana Langdon-Embry, Mithat Gonen, Vinod P. Balachandran, Michael I. D'Angelica, Ronald P. DeMatteo, William R. Jarnagin, T. Peter Kingham, Peter J. Allen, Richard K. Do, Amber L. Simpson

Article Oncology

Regional differences in gallbladder cancer pathogenesis: Insights from a multi-institutional comparison of tumor mutations

Raja R. Narayan, John M. Creasy, Debra A. Goldman, Mithat Gonen, Cyriac Kandoth, Ritika Kundra, David B. Solit, Gokce Askan, David S. Klimstra, Olca Basturk, Peter J. Allen, Vinod P. Balachandran, Michael D'Angelica, Ronald P. DeMatteo, Jeffrey A. Drebin, T. Peter Kingham, Amber L. Simpson, Ghassan K. Abou-Alfa, James J. Harding, Eileen M. O'Reilly, Jean M. Butte, Ryusei Matsuyama, Itaru Endo, William R. Jarnagin

CANCER (2019)

Article Oncology

Peripheral Circulating Tumor DNA Detection Predicts Poor Outcomes After Liver Resection for Metastatic Colorectal Cancer

Raja R. Narayan, Debra A. Goldman, Mithat Gonen, Jonathan Reichel, Kety H. Huberman, Sandeep Raj, Agnes Viale, Nancy E. Kemeny, Peter J. Allen, Vinod P. Balachandran, Michael I. D'Angelica, Ronald P. DeMatteo, Jeffrey A. Drebin, William R. Jarnagin, T. Peter Kingham

ANNALS OF SURGICAL ONCOLOGY (2019)

Article Oncology

Patterns of care for older patients with stage IV non-small cell lung cancer in the immunotherapy era

Kenneth L. Kehl, Michael J. Hassett, Deborah Schrag

CANCER MEDICINE (2020)

Editorial Material Oncology

Racial Disparities in Colorectal Cancer Recurrence and Mortality: Equitable Care, Inequitable Outcomes?

Christopher R. Manz, Deborah Schrag

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)

Article Oncology

Cetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer: BOND-3, an ACCRU Network Randomized Clinical Trial

Marla Lipsyc-Sharf, Fang-Shu Ou, Matthew B. Yurgelun, Douglas A. Rubinson, Deborah Schrag, Shaker R. Dakhil, Philip J. Stella, Douglas J. Weckstein, Donald B. Wender, Meredith Faggen, Tyler J. Zemla, Erica N. Heying, Samantha R. Schuetz, Stephanie Noble, Jeffrey A. Meyerhardt, Tanios Bekaii-Saab, Charles S. Fuchs, Kimmie Ng

Summary: The study investigated the efficacy of combining bevacizumab with irinotecan and cetuximab in patients with irinotecan-refractory metastatic colorectal cancer. Although there was no significant difference in progression-free survival between the two treatment groups, there was a statistically significant improvement in overall survival favoring the group that received bevacizumab in addition to irinotecan and cetuximab. Further investigation on this combination therapy is warranted.

ONCOLOGIST (2022)

Article Oncology

Underutilization of Guideline-Recommended Mismatch Repair/Microsatellite Instability Biomarker Testing in Advanced Colorectal Cancer

David J. Papke Papke Jr, Neal I. Lindeman, Deborah Schrag, J. Bryan Lorgulescu

Summary: Utilization of MMR/MSI testing has increased for advanced colorectal cancer patients, but there is still room for improvement. Testing rates lagged for older patients, those from the poorest households, and those managed at community cancer programs.

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2022)

Article Oncology

Surveillance Imaging vs Symptomatic Recurrence Detection and Survival in Stage II-III Breast Cancer (AFT-01)

Jessica R. Schumacher, Heather B. Neuman, Menggang Yu, David J. Vanness, Yajuan Si, Elizabeth S. Burnside, Kathryn J. Ruddy, Ann H. Partridge, Deborah Schrag, Stephen B. Edge, Ying Zhang, Elizabeth A. Jacobs, Jeffrey Havlena, Amanda B. Francescatti, David P. Winchester, Daniel P. McKellar, Patricia A. Spears, Benjamin D. Kozower, George J. Chang, Caprice C. Greenberg

Summary: This study evaluated the association between different methods of detecting distant recurrence in breast cancer patients and survival rates, finding that asymptomatic imaging detection was associated with better outcomes for patients with estrogen receptor and progesterone receptor negative, HER2 negative or HER2 positive cancers. However, no association was observed in patients with estrogen receptor or progesterone receptor positive, HER2 negative cancers.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2022)

Article Oncology

Elucidating Analytic Bias Due to Informative Cohort Entry in Cancer Clinico-genomic Datasets

Kenneth L. Kehl, Hajime Uno, Alexander Gusev, Stefan Groha, Samantha Brown, Jessica A. Lavery, Deborah Schrag, Katherine S. Panageas

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2023)

Article Medicine, General & Internal

Preoperative Treatment of Locally Advanced Rectal Cancer

Deborah Schrag, Qian Shi, Martin R. Weiser, Marc J. Gollub, Leonard B. Saltz, Benjamin L. Musher, Joel Goldberg, Tareq Al Baghdadi, Karyn A. Goodman, Robert R. McWilliams, Jeffrey M. Farma, Thomas J. George, Hagen F. Kennecke, Ardaman Shergill, Michael Montemurro, Garth D. Nelson, Brian Colgrove, Vallerie Gordon, Alan P. Venook, Eileen M. O'Reilly, Jeffrey A. Meyerhardt, Amylou C. Dueck, Ethan Basch, George J. Chang, Harvey J. Mamon

Summary: Preoperative FOLFOX chemotherapy is as effective as preoperative chemoradiotherapy for locally advanced rectal cancer eligible for sphincter-sparing surgery.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

Article Oncology

Disparities in electronic health record portal access and use among patients with cancer

Joan M. Griffin, Barbara L. Kroner, Sandra L. Wong, Liliana Preiss, Ashley Wilder Smith, Andrea L. Cheville, Sandra A. Mitchell, Nicola Lancki, Michael J. Hassett, Deborah Schrag, Raymond U. Osarogiagbon, Jennifer L. Ridgeway, David Cella, Roxanne E. Jensen, Ann Marie Flores, Jessica D. Austin, Betina Yanez

Summary: This study examined portal access and persistence of portal use and associations with patient and structural factors before the implementation of interventions. The results showed that male sex, membership in a racial and ethnic minority group, rural dwelling, not working, and limited broadband access were associated with lower odds of portal access. Younger age and more clinical encounters were associated with higher odds of portal access. Multiple modalities for portal access, being middle-aged, and having more clinical encounters were associated with persistent portal use. Patient and structural factors affect portal access and use and may exacerbate disparities in cancer symptom surveillance and management.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2023)

Meeting Abstract Gastroenterology & Hepatology

Preoperative Treatment of Locally Advanced Rectal Cancer

D. Schrag, Q. Shi, M. R. Weiser

DISEASES OF THE COLON & RECTUM (2023)

Article Health Care Sciences & Services

Framework for integrating electronic patient-reported data in routine cancer care: an Oncology Intake Questionnaire

Nadine J. McCleary, Ellana K. Haakenstad, Jessica L. F. Cleveland, Michael Manni, Michael J. Hassett, Deb Schrag

Summary: This article describes the development process of the electronic New Patient Intake Questionnaire at the Dana-Farber Cancer Institute, involving various stakeholders and multiple updates in response to feedback. The implementation of the electronic questionnaire improved accessibility and provided more data for patients and clinicians, potentially benefiting cancer care outcomes.

JAMIA OPEN (2022)

Article Oncology

Financial Burden of Discarded Weight-based Antineoplastic Drugs to Payers and Patients in the Private Insurance Market

Ya-Chen Tina Shih, Ying Xu, Hui Zhao, Deborah Schrag, James Yao

Summary: The study estimated the financial burden of discarded weight-based intravenous antineoplastic drugs on private insurers and patients, finding that private payers spent $5090 per patient and patients' mean out-of-pocket expense on discarded drugs was $63. Approximately 39.7% of patients had high-deductible plans, with those in high-deductible plans having significantly higher out-of-pocket expenses for discarded drugs compared to those without.

JNCI CANCER SPECTRUM (2021)

No Data Available